Similar articles

• Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

  Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR; RE-NOVATE Study Group. Eriksson BI, et al. Lancet. 2007 Sep 15;370(9591):949-56. doi: 10.1016/S0140-6736(07)61445-7. Lancet. 2007. PMID: 17869635 Clinical Trial.
• Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.

  Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Noack H, Robinson PA, Dolan G, Brenkel IJ. Wolowacz SE, et al. Thromb Haemost. 2010 Feb;103(2):360-71. doi: 10.1160/TH09-08-0579. Epub 2009 Dec 18. Thromb Haemost. 2010. PMID: 20024501
• An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.

  Lereun C, Wells P, Diamantopoulos A, Rasul F, Lees M, Sengupta N. Lereun C, et al. J Med Econ. 2011;14(2):238-44. doi: 10.3111/13696998.2011.564699. Epub 2011 Mar 9. J Med Econ. 2011. PMID: 21385145
• Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.

  Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E. Stevenson M, et al. Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. Health Technol Assess. 2009. PMID: 19846028 Review.
• Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.

  Holmes M, Carroll C, Papaioannou D. Holmes M, et al. Health Technol Assess. 2009 Sep;13 Suppl 2:55-62. doi: 10.3310/hta13suppl2/08. Health Technol Assess. 2009. PMID: 19804690 Review.